Document is current
Any future updates will be listed below
-
Authors
Ferreira da Silva, Joana
Tou, Connor J. https://orcid.org/0000-0003-2444-4215
King, Emily M. https://orcid.org/0000-0002-3489-3682
Eller, Madeline L.
Rufino-Ramos, David https://orcid.org/0000-0002-5125-9667
Ma, Linyuan
Cromwell, Christopher R.
Metovic, Jasna https://orcid.org/0000-0002-9146-1747
Benning, Friederike M. C. https://orcid.org/0000-0002-1002-4204
Chao, Luke H. https://orcid.org/0000-0002-4849-4148
Eichler, Florian S.
Kleinstiver, Benjamin P. https://orcid.org/0000-0002-5469-0655
-
Funding
Funding for this research was provided by:
U.S. Department of Health Human Services | NIH | NIH Office of the Director (DP2-CA281401)
Massachusetts General Hospital (Howard M. Goodman Fellowship, Kayden-Lambert MGH Research Scholar Award 2023-2028, ECOR FMD Fellowship)
U.S. Department of Health Human Services | NIH | National Heart, Lung, and Blood Institute (P01-HL142494)
U.S. Department of Health Human Services | NIH | National Human Genome Research Institute (UM1-HG012010)
European Molecular Biology Organization (ALTF 750-2022)
National Science Foundation (2020295403)
Friedreich's Ataxia Research Alliance (FARA Fellowship)
Banting Postdoctoral Fellowship - Natural Sciences and Engineering Research Council of Canada
Swiss National Science Foundation | National Center of Competence in Research Quantum Science and Technology (P180777)
U.S. Department of Health Human Services | NIH | National Institute of General Medical Sciences (R35GM142553)
- License Information
-
More Information
Article History
Received: 6 September 2023
Accepted: 24 June 2024
First Online: 22 July 2024
Competing interests
: J.F.d.S., C.J.T. and B.P.K. are inventors on a patent application filed by the MGB that describes click editing. C.J.T. and B.P.K. are inventors on additional patents or patent applications filed by the MGB that describe genome engineering technologies. F.S.E. has consulted for Sanofi, Spur Therapeutics, Taysha, ASPA Therapeutics and Atlas Venture. B.P.K. is a consultant for EcoR1 Capital and Novartis Venture Fund and is on the scientific advisory board of Acrigen Biosciences, Life Edit Therapeutics and Prime Medicine. B.P.K. has a financial interest in Prime Medicine, a company developing therapeutic CRISPR–Cas technologies for gene editing. B.P.K.’s interests were reviewed and are managed by the MGH and MGB in accordance with their conflict-of-interest policies. The other authors declare no competing interests.
